Intellectual Property Portfolio

Geron protects its investments in new technologies through a carefully managed program of international intellectual property protection. Our patent portfolio covers innovations that arose from our internal research as well as technologies created in conjunction with collaborators and in-licensed patents.

Our patent rights relating to imetelstat which have been exclusively licensed to Janssen for all disorders or medical conditions include those covering the nucleic acid sequence of hTR, the RNA component of telomerase, against which the oligonucleotide component of imetelstat is targeted; composition claims to the drug molecule and related telomerase inhibiting molecules; the amidate nucleic acid chemistry used in the oligonucleotide; as well as manufacturing processes for the drug, and method of treatment and kit claims, certain of which are co-owned by us.

Close
Form content here please :)
0